Viatris acquired Aculys Pharma, a clinical-stage biopharmaceutical company, to gain exclusive rights in Japan for treatments targeting narcolepsy and obstructive sleep apnea. This move signals a strategic shift towards investing in innovative, patent-protected assets in key international markets.
Filing excerpt
Viatris continued to advance its pipeline of innovative, best-in-class, patent-protected assets in areas of unmet medical need through accretive in-market business development opportunities, including its October 2025 acquisition of Aculys Pharma, a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions primarily in Japan.
What this signalsIntegration work after a deal often opens needs for new systems and services.
Regions named
sec-10kacquisitionCompletedGet every 10-K signal for Viatris and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Viatris this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/220ce232-d5be-4f88-b735-c3ad4bf189b1 returns this record as JSON. POST /v1/companies/enrich returns every signal for viatris.com.
{
"signal_id": "220ce232-d5be-4f88-b735-c3ad4bf189b1",
"signal_type": "sec-10k",
"signal_subtype": "acquisitionCompleted",
"detected_at": "2026-03-03T06:02:41.098+00:00",
"company": {
"name": "Viatris",
"domain": "viatris.com"
},
"data": {
"detail": "Viatris acquired Aculys Pharma, a clinical-stage biopharmaceutical company, to gain exclusive rights in Japan for treatments targeting narcolepsy and obstructive sleep apnea. This move signals a strategic shift towards investing in innovative, patent-protected assets in key international markets.",
"metrics": {
"timeframe": "current_year"
},
"summary": "Viatris acquired Aculys Pharma in Oct 2025 to expand its innovative neurology pipeline in Japan.",
"excerpts": "Viatris continued to advance its pipeline of innovative, best-in-class, patent-protected assets in areas of unmet medical need through accretive in-market business development opportunities, including its October 2025 acquisition of Aculys Pharma, a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions primarily in Japan.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/vtrs-20251231.htm",
"filing_date": "2026-02-26",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Active integration needs",
"signal_category": "strategic",
"regions_mentioned": [
"Japan",
"Asia-Pacific"
]
}
}
curl https://signals.autobound.ai/v1/signals/220ce232-d5be-4f88-b735-c3ad4bf189b1 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"viatris.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.